Division of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey.
, Vatan Street No: 91, 06200, Yenimahalle/Ankara, Turkey.
Wien Klin Wochenschr. 2024 Jun;136(11-12):340-346. doi: 10.1007/s00508-023-02315-z. Epub 2024 Jan 5.
Comparison of prognosis and survival in human epidermal growth factor receptor 2 (HER2)-low and HER2-negative patients with early stage or locally advanced, hormone receptor-positive breast cancer.
In a retrospective single center study, the patients with early stage or locally advanced stage, hormone receptor (HR)-positive [estrogen receptor (ER) ≥ 1% and/or progesterone receptor (PR) ≥ 1%] and HER2 negative or HER2 low invasive breast cancer diagnosis were included. A total of 444 patients were included in the study. Patients were divided into two groups: HER2 negative and HER2 low. There were 235 (53%) patients in the HER2 negative group and 209 (47%) patients in the HER2 low group.
The HER2 low group had significantly longer 5‑year disease-free survival (DFS) than the HER2 negative group. The patients with lower Ki67 (< 20%) also had a longer 5‑year DFS.
Nonmetastatic HR+/HER2 low breast cancer patients had better DFS than HR+/HER2 negative ones. The Ki67 level and HER2 low status were independent prognostic factors. Randomized clinical trials are needed in early stage HER2 low breast cancer patients.
比较人表皮生长因子受体 2（HER2）低表达和 HER2 阴性的激素受体阳性（HR+）早期或局部晚期乳腺癌患者的预后和生存情况。
在一项回顾性单中心研究中，纳入了 HR+（雌激素受体 [ER]≥1%和/或孕激素受体 [PR]≥1%）且 HER2 阴性或 HER2 低侵袭性乳腺癌诊断的早期或局部晚期患者。共有 444 例患者纳入研究。患者被分为两组：HER2 阴性组和 HER2 低表达组。HER2 阴性组有 235 例（53%）患者，HER2 低表达组有 209 例（47%）患者。
HER2 低表达组的 5 年无病生存率（DFS）显著长于 HER2 阴性组。Ki67 水平较低（<20%）的患者也有更长的 5 年 DFS。
非转移性 HR+/HER2 低表达乳腺癌患者的 DFS 优于 HR+/HER2 阴性患者。Ki67 水平和 HER2 低状态是独立的预后因素。早期 HER2 低表达乳腺癌患者需要进行随机临床试验。
